<p align=center>Email sended at 14-12-2017 11:02:42</p>
              	<li>to:</li>
                <li>headers:From: comitati-etici-toscana@no-reply.it<comitati-etici-toscana@no-reply.it>
BCC: g.contino@cineca.it
CC: silvia.benemei@unifi.it
Reply-To: <>
Return-Path: comitati-etici-toscana@no-reply.it<comitati-etici-toscana@no-reply.it>
Message-ID: <1513249362-comitati-etici-toscana@no-reply.it>
MIME-Version: 1.0
Content-Type: multipart/mixed;
 boundary="84a087ff78cfa64ef32d4982881a85ed"

</li>
                <li>oggetto:Segreteria CEAV Centro - notifica di parere sospensivo</li>
                <li>testo:La segreteria CEAV Centro ha inviato parere sospensivo per lo studio 'A randomized, placebo-controlled, double-blind, parallel-group, multicenter, exploratory dose-response study to assess the efficacy and safety of different oral doses of BAY 1128688 in women with symptomatic
endometriosis over a 12-week treatment period
'.<br> E' possibile visualizzarne i dettagli tramite il seguente link:<br> <a href="https://ricercaclinica-toscana.cineca.it/uxmr/index.php?&exams=visite_exam.xml&ID_STUD=11525">Vai allo studio</a>&nbsp;</li>
                <hr><p align=center>Email sended at 14-12-2017 15:55:18</p>
              	<li>to:</li>
                <li>headers:From: comitati-etici-toscana@no-reply.it<comitati-etici-toscana@no-reply.it>
BCC: g.contino@cineca.it
CC: silvia.benemei@unifi.it
Reply-To: <>
Return-Path: comitati-etici-toscana@no-reply.it<comitati-etici-toscana@no-reply.it>
Message-ID: <1513266918-comitati-etici-toscana@no-reply.it>
MIME-Version: 1.0
Content-Type: multipart/mixed;
 boundary="67d44f7b14c8ce9f378c2a3e9ea2c306"

</li>
                <li>oggetto:Segreteria CEAV Centro - notifica di parere sospensivo</li>
                <li>testo:La segreteria CEAV Centro ha inviato parere sospensivo per lo studio 'A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design Dose-Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery'.<br> E' possibile visualizzarne i dettagli tramite il seguente link:<br> <a href="https://ricercaclinica-toscana.cineca.it/uxmr/index.php?&exams=visite_exam.xml&ID_STUD=11591">Vai allo studio</a>&nbsp;</li>
                <hr><p align=center>Email sended at 14-12-2017 16:54:14</p>
              	<li>to:</li>
                <li>headers:From: comitati-etici-toscana@no-reply.it<comitati-etici-toscana@no-reply.it>
BCC: g.contino@cineca.it
CC: silvia.benemei@unifi.it
Reply-To: <>
Return-Path: comitati-etici-toscana@no-reply.it<comitati-etici-toscana@no-reply.it>
Message-ID: <1513270454-comitati-etici-toscana@no-reply.it>
MIME-Version: 1.0
Content-Type: multipart/mixed;
 boundary="93722f549368be4a3f39cce2b6a17416"

</li>
                <li>oggetto:Segreteria CEAV Centro - notifica di parere sospensivo</li>
                <li>testo:La segreteria CEAV Centro ha inviato parere sospensivo per lo studio 'A Phase 3 Randomized, Open-Label Clinical  Study to  Evaluate the Efficacy and Safety of_Pembrolizumab plus Epacadostat,  Pembrolizurnab Monotherapy, and the EXTREME Regimen  as First line Treatment for Recurrént_or Metastatic Head arid _Neck  Squamous Cell Carcinoma (_KEYNOTE-669/’ECHO-304).'.<br> E' possibile visualizzarne i dettagli tramite il seguente link:<br> <a href="https://ricercaclinica-toscana.cineca.it/uxmr/index.php?&exams=visite_exam.xml&ID_STUD=11973">Vai allo studio</a>&nbsp;</li>
                <hr><p align=center>Email sended at 14-12-2017 18:37:55</p>
              	<li>to:</li>
                <li>headers:From: comitati-etici-toscana@no-reply.it<comitati-etici-toscana@no-reply.it>
BCC: g.contino@cineca.it
CC: silvia.benemei@unifi.it
Reply-To: <>
Return-Path: comitati-etici-toscana@no-reply.it<comitati-etici-toscana@no-reply.it>
Message-ID: <1513276675-comitati-etici-toscana@no-reply.it>
MIME-Version: 1.0
Content-Type: multipart/mixed;
 boundary="3b4080d038320a347a9d52eae279db8d"

</li>
                <li>oggetto:Segreteria CEAV Centro - notifica di parere sospensivo</li>
                <li>testo:La segreteria CEAV Centro ha inviato parere sospensivo per lo studio 'A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant recipients'.<br> E' possibile visualizzarne i dettagli tramite il seguente link:<br> <a href="https://ricercaclinica-toscana.cineca.it/uxmr/index.php?&exams=visite_exam.xml&ID_STUD=11240">Vai allo studio</a>&nbsp;</li>
                <hr>